

Estimate change	↑
TP change	↑
Rating change	↔

Bloomberg	GRAN IN
Equity Shares (m)	243
M.Cap.(INRb)/(USDb)	137.1 / 1.5
52-Week Range (INR)	627 / 412
1, 6, 12 Rel. Per (%)	-4/19/-14
12M Avg Val (INR M)	676

Financials & Valuations (INR b)

Y/E MARCH	FY26E	FY27E	FY28E
Sales	53.4	62.4	72.6
EBITDA	11.6	14.3	16.8
Adj. PAT	5.9	7.9	9.7
EBIT Margin (%)	16.4	17.9	18.4
Cons. Adj. EPS (INR)	23.9	32.0	39.0
EPS Gr. (%)	23.8	34.2	21.7
BV/Sh. (INR)	172.0	202.8	240.8
Ratios			
Net D:E	0.3	0.3	0.2
RoE (%)	14.8	17.1	17.6
RoCE (%)	12.5	14.6	15.4
Payout (%)	5.1	3.7	3.0
Valuations			
P/E (x)	23.7	17.6	14.5
EV/EBITDA (x)	15.3	12.3	10.3
Div. Yield (%)	0.2	0.2	0.2
FCF Yield (%)	-1.6	1.8	2.5
EV/Sales (x)	3.3	2.8	2.4

Shareholding Pattern (%)

As On	Dec-25	Sep-25	Dec-24
Promoter	38.8	38.8	38.8
DII	17.5	17.9	19.6
FII	13.6	14.1	15.9
Others	30.2	29.2	25.7

FII includes depository receipts

CMP: INR565

TP: INR670 (+19%)

Buy

FDF-led mix shift drives the beat

Work in progress to resolve the Gagillapur issue and Peptide-CDMO/ADHD portfolio

- Granules India (GRAN) delivered higher-than-expected revenue/EBITDA/PAT (beat of 10%/11%/7%) for the quarter. Higher formulation (FDF) and intermediates (PFI) sales led to continued improvement in overall performance for the quarter.
- Geographically, Europe's sales scale-up was due to higher off-take from customers and the launch of new products.
- GRAN continued to optimize product offerings towards a higher share of FDF and PFI and used API for captive consumption and less for external sales.
- The complex generics revenue share has increased considerably from 27% YoY to 49% for 3QFY26. Accordingly, the integrated generics' share reduced from 68% of sales to 47% of sales in 3QFY26.
- We raise our earnings estimate by 2.5%/4% for FY26/FY27, factoring in 1) the scale-up, which is driving EBITDA of the Ascelis Peptide CDMO business, 2) the scale-up of the ADHD portfolio in the US, and 3) expanding product offerings across key markets (US/EU/ROW). We value GRAN at 19x 12M forward earnings to arrive at our TP of INR670. **Reiterate BUY.**

A shift towards complex generics improved profitability

- GRAN's 3QFY26 sales grew 22% YoY to INR13.9b (our est. of INR12.1b), with steady momentum in FDF sales and the addition of CDMO sales.
- FDF sales grew 22% YoY to INR10.5b (76% of sales). Intermediate (PFI) sales grew 13% YoY to INR1.5b (11% of sales). API sales grew 9% YoY to INR1.5b (11% of sales). CDMO sales grew 1% QoQ to INR1.5b (2% of sales).
- Gross margin (GM) expanded 220bp to 63.9% due to a better product mix in the FD segment and lower RM costs as a % of sales.
- The EBITDA margin expanded 200bp YoY to 22.2% (our est. of 22%) due to a higher gross profit. Higher employee cost (+150bp YoY as % of sales) was offset by lower other expenses (down 130bp as % of sales).
- EBITDA grew by 34% YoY to INR3.1b (our est. of INR2.8b) for the quarter.
- Adjusted PAT grew by 27.7% YoY to INR1.5b (our estimate: INR1.4b).
- For 9MFY26, the company's revenue/EBITDA/PAT grew 19%/20%/18% to INR39b/INR8.3b/INR4b.

Highlights from the management commentary

- GRAN is on track to achieve an EBITDA break-even in the Peptide/CDMO businesses.
- It met the USFDA with respect to the Gagillapur site. GRAN is likely to submit documents, based on the meeting outcome, to resolve the regulatory issues.
- In addition, as risk mitigation efforts, GRAN has filed select products from the US and GLS facilities.
- Overall, GRAN is expected to exhibit business scale-up and subsequent improvement in profitability going forward.

Tushar Manudhane - Research Analyst (Tushar.Manudhane@MotilalOswal.com)

Eshita Jain - Research Analyst (Eshita Jain @MotilalOswal.com) | **Vipul Mehta** (vipul.mehta@motilaloswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

- The paracetamol-related inventory situation eased at the industry level in certain geographies. Accordingly, GRAN expects a revival in demand for the product.
- GRAN has 8-9 products in the controlled substance category as a part of its complex generics portfolio. It expects 3-4 launches over the medium term.
- Post-EU approvals at the site, GRAN is expected to scale up its business from the Genome site.

Consolidated - Quarterly Earnings Model

Y/E March	FY25				FY26E				FY25	FY26E	FY26E	Var.	
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE					
INRm													
Net Sales	11,799	9,666	11,377	11,974	12,101	12,970	13,879	14,469	44,816	53,419	12,611	10.1	
YoY Change (%)	19.7	-18.7	-1.5	1.8	2.6	34.2	22.0	20.8	-0.5	19.2	10.9		
Total Expenditure	9,206	7,633	9,074	9,451	9,634	10,188	10,799	11,155	35,364	41,775	9,837		
EBITDA	2,593	2,033	2,303	2,524	2,467	2,782	3,081	3,313	9,452	11,644	2,775	11.0	
YoY Change (%)	64.2	-4.5	-8.1	-1.3	-4.8	36.8	33.8	31.3	7.8	23.2	20.5		
Margins (%)	22.0	21.0	20.2	21.1	20.4	21.5	22.2	22.9	21.1	21.8	22.0		
Depreciation	529	525	566	635	688	720	735	740	2,255	2,884	715		
EBIT	2,064	1,508	1,737	1,889	1,779	2,062	2,346	2,573	7,197	8,759	2,060	13.9	
YoY Change (%)	90.0	-6.0	-12.3	-6.7	-13.8	36.7	35.1	36.2	7.5	21.7	18.6		
Margins (%)	17.5	15.6	15.3	15.8	14.7	15.9	16.9	17.8	16.1	16.4	16.3		
Interest	270	257	266	240	238	292	287	283	1,032	1,100	283		
Other Income	21	32	57	19	163	-11	-36	36	129	152	32		
PBT before EO expense	1,814	1,284	1,528	1,668	1,704	1,759	2,022	2,326	6,294	7,812	1,808	11.8	
Extra-Ord expense	0	0	0	-308	259	0	0	0	-308	259	0		
PBT	1,814	1,284	1,528	1,976	1,445	1,759	2,022	2,326	6,601	7,552	1,808	11.8	
Tax	468	311	352	455	319	453	520	547	1,587	1,838	405		
Rate (%)	25.8	24.3	23.0	23.0	22.1	25.7	25.7	23.5	24.0	24.3	22.4		
(Profit)/Loss of JV/Asso. Cos.	0	0	0	0	0	0	0	0	0	0	0		
Reported PAT	1,346	972	1,176	1,520	1,126	1,306	1,502	1,780	5,015	5,714	1,403	7.0	
Adjusted PAT	1,346	972	1,176	1,284	1,328	1,306	1,502	1,780	4,778	5,916	1,403	7.0	
YoY Change (%)	112.7	-4.8	-6.4	-1.0	-1.4	34.3	27.7	38.6	13.6	23.8	19.3		
Margins (%)	11.4	10.1	10.3	10.7	11.0	10.1	10.8	12.3	10.7	11.1	11.1		

E: MOSL Estimates

Key performance Indicators (Consolidated)

Y/E March	FY25				FY26E				FY25	FY26E	FY26E	3Q	
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE					
FD	8,912	7,490	8,674	9,259	8,989	9,657	10,548	10,926	34,335	40,120	9,541		
YoY Change (%)	64.4	1.6	13.7	7.1	0.9	28.9	21.6	18.0	18.0	16.8	10.0		
PFI	997	756	1,309	1,232	1,194	1,331	1,481	1,441	4,294	5,447	1,178		
YoY Change (%)	-32.6	-47.0	-24.5	-16.9	19.8	76.1	13.1	17.0	-29.7	26.9	-10.0		
API	1,890	1,420	1,393	1,483	1,627	1,705	1,515	1,602	6,186	6,449	1,602		
YoY Change (%)	-36.1	-52.2	-36.6	-9.2	-13.9	20.1	8.8	8.0	-37.0	4.2	15.0		
Cost Break-up													
RM Cost (% of Sales)	41.1	38.0	38.3	36.6	35.1	34.3	36.1	35.8	61.5	64.6	34.5		
Staff Cost (% of Sales)	13.9	16.5	14.7	14.1	16.8	16.9	16.3	15.5	14.7	16.3	16.2		
Other Cost (% of Sales)	23.1	24.5	26.7	28.2	27.7	27.3	25.4	25.8	25.7	26.5	27.3		
Gross Margins (%)	58.9	62.0	61.7	63.4	64.9	65.7	63.9	64.2	38.5	35.4	65.5		
EBITDA Margins (%)	22.0	21.0	20.2	21.1	20.4	21.5	22.2	22.9	21.1	21.8	22.0		
EBIT Margins (%)	17.5	15.6	15.3	15.8	14.7	15.9	16.9	17.8	16.1	16.4	16.3		

E: MOSL Estimates




Key highlights from the management commentary

- Consultancy costs related to remediation measures at Gagiallapur largely moderated in 3QFY26.
- GRAN received the ANVISA Brazil GMP certificate for the Gagillapur site.
- Tentative approval received for Amphetamine ER (Adzenys) ANDA in Q3FY26.
- Capex during the quarter stood at INR1.3b.
- GRAN filed about 36 products (five in 9MFY26) across focus markets and is awaiting approval.
- R&D spend was INR690m and formed 5% of sales.
- Net debt was INR10.1b at the end of 3QFY26.


Key exhibits

Exhibit 1: Revenue grew 22% YoY in 3QFY26



Source: MOFSL, Company

Exhibit 2: EBITDA margin expanded 200bp YoY in 3QFY26



Source: MOFSL, Company

Recovery gaining traction due to CDMO scale-up/regulatory progress

Peptide push/focus on the high-value segment to drive the recovery

- GRAN delivered FDF sales of 16% YoY/22% YoY in 9MFY26/3QFY26.
- Notably, the FDF share in 3QFY26 revenue was 76%, driven by the scale-up of the ADHD portfolio.
- The complex generics segment's share has significantly scaled up to 49% in 3QFY26 vs 27% in 3QFY25. Notably, GRAN's focus has shifted to high-value/complex therapies such as oncology over the medium to long term.
- GRAN has 8-9 products in the controlled substance category as a part of its complex generics portfolio. It expects 3-4 launches over the medium term.
- The ramp-up of supplies from the Genome Valley facility will further strengthen the US business. GRAN plans 2 product launches from the Genome facility over the next two quarters. Post EU approval, the site is positioned for additional approvals.
- The Peptide Centre of Excellence at IIT Hyderabad is now operational and contributing directly to customer projects, including development & execution.
- FDF sales were driven by productivity gains/Genome Valley supply/site remediation/strong performance in the controlled substances portfolio. We expect a 15% sales CAGR in the FDF segment over FY25-28 to reach INR52.8b.

Gagillapur remediation on track/Genome Valley scale up to fuel growth

- GRAN made steady progress across all its facilities in 3QFY26, with the remediation plan at the Gagillapur facility remaining on track. The management is in the process of submitting the requested documents post the recent meeting with the USFDA. GRAN expects to receive formal feedback after submission and remains confident about the pathway to resolution. GRAN received the ANVISA Brazil GMP certificate for the Gagillapur site.
- As a prudent de-risking measure, GRAN has filed select products from its US and GLS facilities. The Genome Valley facility underwent a surprise USFDA inspection and received 5 observations, none related to data integrity. Earlier this quarter, GLS received PAS approval/EIR following an inspection held in Aug'25.
- The GRAN's packaging facility underwent a USFDA inspection with no observation.

Reiterate BUY

- We raise our earnings estimate by 2.5%/4% for FY26/FY27, factoring in 1) the scale-up, which is driving EBITDA of the Ascelis Peptide CDMO business, 2) the scale-up of the ADHD portfolio in the US, and 3) expanding product offerings across key markets (US/EU/ROW).
 - We value GRAN at 19x 12M forward earnings to arrive at our TP of INR670.
- Reiterate BUY.**

Exhibit 3: P/E chart






Exhibit 4: EV/EBITDA chart




Story in charts

Exhibit 5: Expect a revenue CAGR of ~17% over FY25-28




Source: MOFSL, Company

Exhibit 6: EBITDA margin to expand 200bp over FY25-28




Source: MOFSL, Company

Exhibit 7: Expect FD to increase to 78% in FY28




Source: MOFSL, Company

Exhibit 8: FDF sales to clock a 21% CAGR over FY25-28E




Source: MOFSL, Company

Exhibit 9: PAT to exhibit a 25% CAGR over FY25-28



Source: MOFSL, Company

Exhibit 10: Return ratios in an uptrend over FY25-28



Source: MOFSL, Company

Financials and valuations

Consolidated - Income Statement							(INR m)
Y/E March	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Total Income from Operations	37,477	45,119	45,063	44,816	53,419	62,404	72,590
Change (%)	15.8	20.4	-0.1	-0.5	19.2	16.8	16.3
Total Expenditure	30,427	35,901	36,293	35,364	41,775	48,113	55,822
% of Sales	81.2	79.6	80.5	78.9	78.2	77.1	76.9
EBITDA	7,050	9,218	8,770	9,452	11,644	14,290	16,768
Margin (%)	18.8	20.4	19.5	21.1	21.8	22.9	23.1
Depreciation	1,586	1,845	2,073	2,255	2,884	3,112	3,400
EBIT	5,464	7,373	6,697	7,197	8,759	11,178	13,368
Int. and Finance Charges	232	559	1,058	1,032	1,100	1,000	938
Other Income	176	138	44	129	152	156	181
PBT bef. EO Exp.	5,407	6,952	5,683	6,294	7,812	10,334	12,611
EO Items	173	-80	-211	308	-259	0	0
PBT after EO Exp.	5,580	6,872	5,472	6,601	7,552	10,334	12,611
Current Tax	1,382	1,772	1,652	1,828	1,752	2,397	2,926
Deferred Tax	70	-66	-233	-242	-327	0	0
Tax Rate (%)	26.0	24.8	25.9	24.0	18.9	23.2	23.2
Add: Associate income	0	0	0	0	0	0	0
Reported PAT	4,128	5,166	4,052	5,015	5,714	7,936	9,686
Adjusted PAT	4,000	5,224	4,207	4,778	5,916	7,936	9,686
Change (%)	-27.6	30.6	-19.5	13.6	23.8	34.2	22.0
Margin (%)	10.6	11.5	9.3	10.6	11.0	12.7	13.3

Consolidated - Balance Sheet							(INR m)
Y/E March	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Equity Share Capital	248	242	242	243	248	248	248
Total Reserves	25,617	28,107	32,013	36,913	42,338	49,984	59,380
Net Worth	25,865	28,349	32,255	37,156	42,585	50,232	59,628
Minority Interest	6	0	0	0	0	0	0
Deferred Liabilities	139	77	231	314	314	314	314
Total Loans	10,928	11,362	13,151	14,548	13,752	12,922	12,092
Capital Employed	36,938	39,788	45,637	52,017	56,650	63,467	72,033
Gross Block	25,355	30,897	34,817	40,381	46,381	50,881	55,381
Less: Accum. Deprn.	9,943	11,788	13,861	16,116	19,000	22,113	25,513
Net Fixed Assets	15,412	19,109	20,956	24,265	27,380	28,768	29,868
Capital WIP	3,562	2,394	2,717	4,402	5,342	4,992	5,807
Total Investments	197	361	382	426	426	426	426
Curr. Assets, Loans&Adv.	25,945	27,168	30,783	32,755	35,144	41,169	49,798
Inventory	9,786	11,494	13,005	13,428	15,680	17,795	20,646
Account Receivables	9,250	9,485	9,858	9,422	13,465	14,874	17,302
Cash and Bank Balance	4,095	3,128	3,864	5,964	1,302	2,259	4,590
Loans and Advances	2,815	3,060	4,056	3,941	4,698	6,240	7,259
Curr. Liability & Prov.	8,191	9,258	9,573	10,509	12,320	12,566	14,544
Account Payables	6,386	7,821	7,495	7,261	8,813	10,282	11,929
Other Current Liabilities	1,294	998	1,580	2,614	3,115	1,872	2,178
Provisions	511	439	497	634	392	412	437
Net Current Assets	17,753	17,910	21,211	22,247	22,824	28,603	35,254
Appl. of Funds	36,938	39,788	45,637	52,017	56,651	63,467	72,033

Financials and valuations

Ratios

Y/E March	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
EPS	16.5	21.5	17.3	19.7	23.9	32.0	39.1
Cash EPS	22.5	29.2	25.9	29.0	35.5	44.6	52.8
BV/Share	104.3	117.1	133.1	153.2	172.3	203.2	241.1
DPS	1.0	1.0	1.0	1.0	1.0	1.0	1.0
Payout (%)	7.0	5.5	7.0	5.7	4.7	3.7	3.0
Valuation (x)							
P/E	34.3	26.2	32.6	28.7	23.7	17.6	14.4
Cash P/E	25.1	19.3	21.8	19.5	15.9	12.7	10.7
P/BV	5.4	4.8	4.2	3.7	3.3	2.8	2.3
EV/Sales	4.6	3.9	3.9	3.9	3.3	2.8	2.4
EV/EBITDA	24.5	18.9	20.0	18.4	15.3	12.3	10.3
Dividend Yield (%)	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Return Ratios (%)							
RoE	16.8	19.3	13.9	13.8	14.8	17.1	17.6
RoCE	12.6	14.8	11.7	11.5	13.4	14.5	15.4
RoIC	15.1	17.6	13.7	13.7	15.7	16.3	17.5
Working Capital Ratios							
Asset Turnover (x)	1.0	1.1	1.0	0.9	0.9	1.0	1.0
Inventory (Days)	86	86	99	108	99	98	97
Debtor (Days)	82	76	78	79	78	83	81
Creditor (Days)	71	72	77	76	70	72	73
Leverage Ratio (x)							
Current Ratio	3.2	2.9	3.2	3.1	2.9	3.3	3.4
Interest Cover Ratio	24	13	6	7	8	11	14
Debt/Equity	0.4	0.4	0.4	0.4	0.3	0.3	0.2

Consolidated - Cash Flow Statement

Y/E March	FY22	FY23	FY24	FY25	FY26E	FY27E	INRm FY28E
OP/(Loss) before Tax	5,580	6,952	5,472	6,294	7,812	10,334	12,611
Depreciation	1,586	1,845	2,073	2,255	2,884	3,112	3,400
Interest & Finance Charges	232	559	1,058	903	948	844	757
Direct Taxes Paid	-1,450	-1,758	-1,903	-1,587	-1,838	-2,397	-2,926
(Inc)/Dec in WC	-2,572	-103	-2,463	1,064	-5,239	-4,822	-4,320
CF from Operations	3,376	7,495	4,238	8,930	4,566	7,071	9,522
Others	-56	-27	156	0	-259	0	0
CF from Operating incl EO	3,321	7,467	4,394	8,930	4,307	7,071	9,522
(inc)/dec in FA	-3,967	-4,107	-3,788	-7,248	-6,940	-4,150	-5,315
(Pur)/Sale of Investments	0	2,035	159	-43	0	0	0
Others	166	158	28	129	152	156	181
CF from Investments	-3,801	-1,914	-3,602	-7,163	-6,788	-3,994	-5,133
Issue of Shares	37	-3,084	32	169	5	0	0
(Inc)/Dec in Debt	2,530	-600	1,435	1,397	-796	-830	-830
Interest Paid	-242	-533	-1,027	-1,032	-1,100	-1,000	-938
Dividend Paid	-372	-186	-363	-284	-290	-290	-290
CF from Fin. Activity	1,900	-4,403	77	333	-2,180	-2,120	-2,058
Inc/Dec of Cash	1,419	1,151	869	2,100	-4,662	957	2,331
Opening Balance	2,711	4,095	3,128	3,863	5,964	1,302	2,259
FX	-35	-2,118	-134	0	0	0	0
Closing Balance	4,095	3,128	3,863	5,964	1,302	2,259	4,590

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may: (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

1. Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies).
MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
Nature of Financial interest is holding equity shares or derivatives of the subject company
2. Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
3. Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
4. Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
5. Research Analyst has not served as an officer, director or employee of subject company(ies).
6. MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.

8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

financial interest in the subject company

actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.

received compensation/other benefits from the subject company in the past 12 months

any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

acted as a manager or co-manager of public offering of securities of the subject company in past 12 months

be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)

received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions-including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alterations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN .. 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrivances@motilaloswal.com.